Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIG-101 in Healthy and Asthmatic Participants
NCT07488897Phase 2Recruiting
- Sponsor
- RIGImmune
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of SLR14 in asthma, sponsored by RIGImmune. Started Feb 2026; status: recruiting.
02
Drugs
SLR14
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07488897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488897.